The performance of companies tied to the drug's legacy presents a complex investment picture . While the initial boom generated substantial profits , generic alternatives have significantly diminished sales . Investing in connected pharmaceutical businesses now requires a discerning assessment of proprietary safeguards, evolving medical changes, an